From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: GENI

Search articles by EPIC code
EPIC GENI
views

GENinCode – ‘license approval’, how major an advance in the company's commercial programme?

GENinCode (GENI) has announced “a major advance in the company's commercial programme” – California state licensing approval and CLIA certification of its Irvine laboratory in California, enabling the provision of its products for the risk assessment of CVD to patients across 49 states in the United States. So what’s the detail and what of a current share price response towards 21p, up 170%?!
Page 1 of 1 (1 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments